PremiumThe FlyContext Therapeutics initiated with an Outperform at William Blair Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion Context Therapeutics Begins Phase 1 Trial for CT-95 PremiumRatingsPromising Clinical Trials and Strategic Pipeline Position Context Therapeutics for Success: A Buy Rating Justified Context Therapeutics Advances CTIM-76 in Clinical Pipeline Context doses first patient in Phase 1 clinical trial evaluating CTIM-76 PremiumThe FlyContext Therapeutics initiated with a Buy at D. Boral Capital Context Therapeutics: Strategic Developments and Financial Outlook Context Therapeutics files $250M mixed securities shelf 
